Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice

Yazici S., Kim S., Busby J., He J., Thaker P., Yokoi K., ...More

PROSTATE, vol.65, no.3, pp.203-215, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 65 Issue: 3
  • Publication Date: 2005
  • Doi Number: 10.1002/pros.20283
  • Journal Name: PROSTATE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.203-215
  • Keywords: prostate cancer, EGF-R and VEGF-R phosphorylation, antivascular therapy, RECEPTOR TYROSINE KINASE, CELL LUNG-CANCER, MICROVASCULAR HYPERPERMEABILITY, CLINICAL-SIGNIFICANCE, EGF RECEPTOR, TUMOR-CELLS, EXPRESSION, ANGIOGENESIS, PROGRESSION, BLOCKADE
  • Hacettepe University Affiliated: Yes

Abstract

BACKGROUND. Androgen-independent prostate cancer (PCa) may be susceptible to modulation of the tumor microenvironment. We determined whether a dual tyrosine kinase inhibitor (AEE788) of the epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) combined with chemotherapy can produce therapy of human PCa in nude mice.